Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide

PHASE3TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Epilepsy, Partial
Interventions
DRUG

Lacosamide

4-Week Titration Period: start dose Lacosamide (LCM) is 100 mg/day - up-titration of 100 mg/week LCM 8-Week Maintenance Period: dose can change first 4 weeks with 100 mg/week, must remain between 300 mg/day and 600 mg/day. Dose must remain stable last 4 weeks.

DRUG

Levetiracetam

Levetiracetam (LEV) is taken at a stable dose 30 days before study entry and is ≥ 1000 mg/day at the first visit. The LEV dose may not be changed at any time.

Trial Locations (7)

Unknown

11, Innsbruck

12, Salzburg

2, Bielefeld

1, Bonn

5, Erlangen

22, Alcorcón

20, Santiago de Compostela

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UCB Pharma

INDUSTRY

NCT01375374 - Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide | Biotech Hunter | Biotech Hunter